October 2009
Worldwide Biotech;Oct2009, Vol. 21 Issue 10, p3
Trade Publication
The articles reports that Santhera Pharmaceuticals and Biovail Corporation have signed a license agreement for Santhera's JP-1730/fipamezole. It states that Biovail, which is considered a key player in the area of neurodegenerative disorders, acquired the U.S. and Canadian rights to develop and commercialize the drug for the treatment of Dyskinesia in Parkinson's Disease.


Related Articles

  • Santhera, Biovail in $192M Pact for Parkinson's Drug Fipamezole. Sheridan, Cormac // BioWorld International;8/26/2009, Vol. 14 Issue 34, p1 

    The article reports on a partnership formed by Santhera Pharmaceuticals Holding AG with Biovail Corp. for the Parkinson's drug fipamezole. Under the collaboration, Santhera could receive up to 192 million U.S. dollars from Biovail worth of up-front, development, regulatory and commercial...

  • Biovail acquires rights to develop Santhera's dyskinesia drug.  // PharmaWatch: CNS;Oct2009, Vol. 8 Issue 10, p6 

    The article reports that Bioavail Laboratories International has agreed with Santhera Pharmaceuticals Switzerland to develop and market Santhera's JP-1730/fipamezole, a drug for treating dyskinesia in Parkinson's disease, in Canada and U.S. It notes that their agreement requires Bioavail to make...

  • Ipsen Exits Santhera Agreement on Fipamezole. Sheridan, Cormac // BioWorld International;1/25/2012, Vol. 17 Issue 4, p1 

    The article reports on the search of Santhera Pharmaceuticals AG for a new partner for fipamezole, its Parkinson's disease drug, following the decision of Ipsen SA to return its rights to the drug. Ipsen's rights to the drug cover territories outside of North America and Japan. It explains the...

  • Santhera, Biovail in $192M Pact for Parkinson's Drug Fipamezole. Sheridan, Cormac // BioWorld Today;8/25/2009, Vol. 20 Issue 163, p1 

    The article reports on the partnership of Santhera Pharmaceuticals Holding AG with Biovail Corp. for the development, regulatory and commercial milestones for North American rights to the Parkinson's drug fipamezole. Biovail is expected to pay as much as 192 million U.S. dollars for the rights...

  • Santhera, Ipsen in $181M Fipamezole Collaboration.  // Bioworld Week;9/13/2010, Vol. 18 Issue 37, p2 

    The article reports that Santhera Pharmaceuticals Holding AG has entered into a 141 million-euro deal with Ipsen Group SA for its Fipamezole Parkinson's disease drug.

  • Deal watch : Santhera licenses novel dyskinesia therapy to Biovail.  // Nature Reviews Drug Discovery;Oct2009, Vol. 8 Issue 10, p762 

    The article discusses the agreement between Biovail Laboratories Inc. and Santhera Pharmaceuticals Holding AG entitling Biovail the rights to develop and commercialize fipamezole also known as JP-1730 in Canada an U.S. It mentions that fipamezole is generated to treat levodopa-induced dyskinesia...

  • Santhera In-Licenses Novartis Drug For Muscular Dystrophy. Sheridan, Cormac // BioWorld International;7/4/2007, Vol. 12 Issue 27, p1 

    The article reports that Santhera Pharmaceuticals AG has closed a licensing deal with Novartis AG for the use of omigapil (SNT-317). SNT-317 is a compound that has a potential to treat predominant forms of congenital muscular dystrophy. Santhera would gain access to preclinical and clinical data...

  • Santhera Regains N. American Rights to Parkinson's Drug. Sheridan, Cormac // BioWorld International;10/27/2010, Vol. 15 Issue 42, p3 

    The article reports on the decision of Valeant Pharmaceutical International Inc. to end its partnership with Santhera Pharmaceuticals AG in a deal involving the company's Parkinson's disease drug fipamezole. Despite the loss, Santhera claims that it will not have a significant impact on the...

  • Santhera, Ipsen Sign $181M Collaboration for Fipamezole. Sheridan, Cormac // BioWorld International;9/8/2010, Vol. 15 Issue 35, p1 

    The article reports on the collaboration of Santhera Pharmaceuticals AG with Ipsen Group SA for Fipamezole, a Parkinson's drug. Fipamelone would treat Levodopa-induced dyskinesia, a problem that develops in 25 to 30 percent of all Parkinson's patients. It is also reported that despite the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics